Analytical Data
-
Gene name
FGFR-1 beta (IIIc)
- Application
-
Alternative Names
Fibroblast growth factor receptor 1; FGFR-1; BFGFR; FLT-2; CD331; CEK; FGFBR, FLG
-
Species
Human
-
Source
HEK293
-
Tag
C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P11362-14
-
Expression Region
R22-E285
-
AA Sequence
MWSWKCLLFWAVLVTATLCTARPSPTLPEQDALPSSEDDDDDDDSSSEEKETDNTKPNPVAPYWTSPEKMEKKLHAVPAAKTVKFKCPSSGTPNPTLRWLKNGKEFKPDHRIGGYKVRYATWSIIMDSVVPSDKGNYTCIVENEYGSINHTYQLDVVERSPHRPILQAGLPANKTVALGSNVEFMCKVYSDPQPHIQWLKHIEVNGSKIGPDNLPYVQILKTAGVNTTDKEMEVLHLRNVSFEDAGEYTCLAGNSIGLSHHSAWLTVLEALEERPAVMTSPLYLE
-
Protein Length
Partial
-
Molecular Weight
50-55 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Fibroblast Growth Factor Receptor 1 (FGFR1) is a key receptor in the fibroblast growth factor (FGF) signaling pathway, which plays a crucial role in various biological processes, including cell proliferation, differentiation, and angiogenesis. Among its isoforms, FGFR1 beta (IIIc) is particularly significant due to its involvement in developmental biology and its implication in several cancers. Alterations in FGFR1 signaling have been associated with oncogenesis, making it a potential therapeutic target. Research on FGFR1 beta (IIIc) recombinant proteins aims to elucidate the structure-function relationships of this receptor, enabling a better understanding of its role in tumorigenesis and tissue regeneration. Additionally, these studies can help in the design of FGFR inhibitors, which may serve as novel treatments for diseases linked to aberrant FGFR signaling. Understanding the interactions between FGFR1 beta (IIIc) and its ligands, as well as downstream signaling pathways, is critical for developing targeted therapies and improving clinical outcomes for patients with FGFR-related conditions.
